Cerca
  • Keto strong Official Website To Buy Now
    BENEFITS OF Keto strong
    Lose Weight
    Burn Fat in Trouble Areas
    Get into Ketosis Fast!*
    Burn Fat for Energy (without the jitters)!
    Better Brain Health!
    HOW DOES IT WORK?
    KETOSIS FORCES YOUR BODY TO BURN FAT FOR ENERGY INSTEAD OF CARBS.
    WHY KETO WORKS!
    Ketosis is the state where your body is actually burning fat for energy instead of carbs. Ketosis is extremely hard to obtain on your own and takes weeks to accomplish. Keto strong pill reviews actually helps your body achieve ketosis fast and helps you burn fat for energy instead of carbs!

    Keto strong pill reviews contains Beta-hydroxybutyrate. BHB is the first substrate that kicks the metabolic state of ketosis into action. Revisiting the scenario from before, if you either take supplemental forms or if your body is making beta-hydroxybutyrate, it is able to start processing in your body resulting in energy.
    Click Here To Visit Our official Websites>>>>>
    https://sites.google.com/view/keto-strong-pill-reviews/home
    https://www.facebook.com/Keto-Strong-Review-Negative-Side-Effects-or-Extra-Strength-107692011684646
    https://nutrafame.com/2021/10/19/keto-strong-weightloss-formula-for-united-states/

    https://www.facebook.com/Keto-strong-Canada-101477875662892
    https://kit.co/ketostrongcanada/keto-strong-canada
    https://groups.google.com/g/keto-strong-reviews---scam-or-are-ketostrong-diet-pills-legit/c/azO-6TZuBKg
    https://www.spreaker.com/user/15380140
    https://www.spreaker.com/show/keto-strong-pill-reviews-100-legit
    https://www.inkitt.com/Keto_strong_Better_Dieting
    https://issuu.com/donnajeboeuf/docs/keto_strong_diet_pills-converted
    https://kit.co/ketostrong-diet-pills/keto-strong-better-dieting-support
    https://issuu.com/dnnamayugh/docs/keto_strong_diet_pills-converted_1_
    https://issuu.com/dnnamayugh/docs/keto_strong_diet_pills-converted_1_/s/13579611
    https://www.completefoods.co/diy/recipes/keto-strong-pills-reviews-how-does-it-work-or-scam-2021
    https://www.homify.in/projects/1047910/keto-strong-pill-reviews
    https://www.completefoods.co/diy/recipes/keto-strong-pill-reviews
    https://www.homify.in/projects/1047923/keto-strong-reviews-scam-or-are-ketostrong-diet-pills-legit
    https://www.kemovebbs.com/Thread-BENEFITS-OF-KETO-STRONG-PILLS
    https://www.completefoods.co/diy/recipes/keto-strong-pills-reviews-how-does-it-work-or-scam-2021
    https://www.facebook.com/Keto-strong-pill-reviews-111083061340508
    https://www.kemovebbs.com/Thread-BENEFITS-OF-KETO-STRONG-PILLS
    https://www.weddingwire.com/wedding-forums/benefits-of-keto-strong-pills/8a4840eb1bd07bcf.html
    https://www.instagram.com/ketostrongpillreviews/
    https://twitter.com/StrongPill
    https://www.facebook.com/Keto-Strong-Review-Negative-Side-Effects-or-Extra-Strength-107692011684646
    https://keto-strong-pill-reviews-1.jimdosite.com/
    https://ketostrongpillreviewsus.tumblr.com/
    https://promosimple.com/giveaways/keto-srong-diet-pills-reviews-benefits-or-not-a-scam/
    https://promosimple.com/giveaways/keto-strong-pills-ingredents/
    https://nutrafame.com/2021/10/19/keto-strong-weightloss-formula-for-united-states/
    https://www.kemovebbs.com/Thread-Keto-Strong-Reviews-%E2%80%93-Serious-Scam-Pill-Dangers-or-Is-It-100-Legit
    https://promosimple.com/giveaways/keto-strong-reviews-scam-risk-fake-side-effects-shocking-price-shark-tank-buy-us/


    https://issuu.com/phyllismitcham/docs/keto_strong_usa_best_keto_diet_pills_really_worked
    https://dribbble.com/strongdiet/about
    https://www.stageit.com/ketostrongusdietpill
    https://promosimple.com/giveaways/keto-strong-1-weight-loss-formula-official-website-to-buy-now/
    https://promosimple.com/giveaways/keto-strong-1-trend-weight-loss-product-in-united-states-us/


    0 0 Commenti 0 Shares
  • The targeted protein degradation market is projected to grow at an annualized rate of more than 30% till 2030

    Roots Analysis has done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

    To order this 330+ page report, which features 130+ figures and 145+ tables, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

    Key Market Insights
     More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are 25+ technology platforms available for use in therapy development efforts
     The pipeline features a variety of candidate drugs that target a wide range of disease-causing / associated proteins; majority of the existing drug candidates are designed for administration via non-invasive routes
     Although start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also engaged in this domain
     Close to 5,500 patients were estimated to have been enrolled in clinical trials worldwide, evaluating a number of relevant pre-marketing end points across various phases of development
     A number of prominent scientists from renowned universities have emerged as key opinion leaders, owing to their active involvement in clinical development efforts
     Published scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on PROTACs
     Foreseeing a lucrative future, several private and public investors have invested over USD 3.5 billion across close to 100 instances of funding since 2014
     The increasing interest in this field is also reflected in recent partnership activity; most of these deals are focused on novel technology platforms, involving the active participation of both international and indigenous companies
     Short term opportunity in this market is likely to be driven by licensing activity, depending on the capability of novel technologies to meet protein degrader design and development needs
     As multiple mid-late stage drug candidates are approved for marketing, the long term opportunity is likely to be distributed across different types of protein degraders, target therapeutic areas and various global regions

    For more information please visit:
    https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

    Table of Contents

    1. PREFACE
    1.1. Scope of the Report
    1.2. Research Methodology
    1.3. Chapter Outlines

    2. EXECUTIVE SUMMARY

    3. INTRODUCTION
    3.1. Context and Background
    3.2. Concept of Protein Homeostasis
    3.3. Discovery of the Ubiquitin Proteasome System
    3.3.1. Ubiquitin: Structure and Function
    3.3.2. Fundamentals of the UPS
    3.3.3. Components of the UPS

    3.4. Key Steps Involved in the UPS
    3.4.1. Ubiquitination: The First Step
    3.4.2. Proteasomal Degradation: The Second Step

    3.5. Therapeutic Applications of the UPS
    3.6. Advantages and Challenges Associated with Ubiquitin Enzyme Inhibitors
    3.7. Targeted Protein Degradation: Enhancing Ubiquitination to Degrade Undruggable Targets
    3.7.1. Brief History of Targeted Protein Degradation

    3.8. Types of Protein Degraders
    3.8.1. Selective Hormone Receptor Degraders (SHRDs)
    3.8.2. Immumodulatory Imide Drugs (IMiDs)
    3.8.3. PROTACs
    3.8.4. Other Chimeras (ENDTACs, LYTACs and PHOTACs)
    3.8.4.1. Endosome Targeting Chimeras (ENDTACs)
    3.8.4.2. Lysozyme targeting chimeras (LYTACs)
    3.8.5. Specific and Nongenetic Inhibitor-of-Apoptosis Proteins (IAP)-dependent Protein Erasers (SNIPERS)
    3.8.6. Hydrophobic Tag
    3.8.7. Molecular Glues
    3.8.8. DUB Inhibitors

    3.9. Growth Drivers and Roadblocks

    4. CURRENT MARKET LANDSCAPE
    4.1. Chapter Overview
    4.2. Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline
    4.2.1. Analysis by Type of Protein Degrader
    4.2.2. Analysis by Phase of Development
    4.2.3. Analysis by Therapeutic Area
    4.2.4. Analysis by Target Indication
    4.2.5. Analysis by Type of Target Enzyme
    4.2.6. Analysis by Type of Target Protein
    4.2.7. Analysis by Type of Therapy
    4.2.8. Analysis by Route of Administration

    4.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Research Tools / Key Technology Platforms

    4.4. Targeted Protein Degradation-based Therapeutics and Technologies: Developer Landscape
    4.4.1. Analysis by Year of Establishment
    4.4.2. Analysis by Location of Headquarters
    4.4.3. Analysis by Size of Company
    4.4.4. Analysis by Type of Protein Degrader

    5. COMPANY PROFILES
    5.1. Chapter Overview
    5.2. Developers with Clinical Candidates
    5.2.1. Radius Health
    5.2.1.1. Company Overview
    5.2.1.2. Targeted Protein Degradation-based Drug Portfolio
    5.2.1.2.1. Product Description: Elacestrant
    5.2.1.3. Recent Developments and Future Outlook

    5.2.2. Celgene
    5.2.2.1. Company Overview
    5.2.2.2. Financial Information
    5.2.2.3. Targeted Protein Degradation-based Drug Portfolio
    5.2.2.3.1. Avadomide (CC-122)
    5.2.2.3.2. Iberdomide (CC-220)
    5.2.2.4. Recent Developments and Future Outlook

    5.2.3. Sanofi Genzyme
    5.2.3.1. Company Overview
    5.2.3.2. Financial Information
    5.2.3.3. Targeted Protein Degradation-based Drug Portfolio
    5.2.3.3.1. Product Description: SAR439859
    5.2.3.4. Recent Developments and Future Outlook


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Gaurav Chaudhary
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Targeted Protein Degradation Market | Industry Analysis | Market Size | 2030
    Research report on the future opportunity of targeted protein degradation therapeutics and technology platforms
    WWW.ROOTSANALYSIS.COM
    0 0 Commenti 0 Shares
  • ➢ Product Name—Lean Time Keto
    ➢ Composition—Natural Organic Compound
    ➢ Side-Effects—NA
    ➢ Price—($39.60)
    ➢ Availability—Online
    ➢ Rating : ⭐⭐⭐⭐⭐
    ➢Official Website (Sale Is Live)-- http://nutrafame.com/
    Lean time keto pill reviews
    Lean time keto pill reviews with BHB is here to stay because of the insurmountable success people are having losing up to 1lb of fat per day!
    BENEFITS OF LEAN TIME KETO
    Lose Weight
    Burn Fat in Trouble Areas
    Get into Ketosis Fast!*
    Burn Fat for Energy (without the jitters)!
    Better Brain Health!
    Faster Recovery from Exercise!
    Maintain Lean Muscle!
    WHY DOES IT HAVE SCIENTISTS, DOCTORS AND CELEBRITIES BUZZING?
    The most talked about weight loss product is finally here! A powerful fat burning ketone, BHB has been modified to produce a instant fat burning solution the natural way. Beta-hydroxybutyrate is the first substrate that kicks the metabolic state of ketosis into action. If you take it, BHB is able to start processing in your body resulting in energy and greatly speed up weight loss by putting your body into ketosis. This one BHB Supplement is a revolutionary breakthrough that has the Media in a frenzy!
    HOW DOES IT WORK?
    KETOSIS FORCES YOUR BODY TO BURN FAT FOR ENERGY INSTEAD OF CARBS.
    WHY YOUR DIETS FAIL...
    Currently with the massive load of carbohydrates in our foods, our bodies are conditioned to burn carbs for energy instead of fat. Because it is an easier energy source for the body to use up.
    THE PROBLEM:
    1. Fat stores in the body as carbs are burned as an easy energy fuel. Essentialy we gain more weight year after year.
    2. Carbs are not the body’s ideal source of energy therefore we are usually left feeling tired, stressed and drained at the end of each day.
    WHY KETO WORKS!
    Ketosis is the state where your body is actually burning fat for energy instead of carbs. Ketosis is extremely hard to obtain on your own and takes weeks to accomplish. Lean time keto pill reviews actually helps your body achieve ketosis fast and helps you burn fat for energy instead of carbs!
    THE SOLUTION:
    1. When your body is in ketosis, you are actually burning stored fat for energy and not carbs!
    2. Fat IS the body’s ideal source of energy and when you are in ketosis you experience energy and mental clarity like never before and of course very rapid weight loss.
    BURN FAT
    INSTEAD OF CARBS
    WITH LEAN TIME KETO PILL REVIEWS!
    THE 30 DAY KETOSIS SUPPLEMENT THAT IS SWEEPING THE NATION!
    Lean time keto pill reviews contains Beta-hydroxybutyrate. BHB is the first substrate that kicks the metabolic state of ketosis into action. Revisiting the scenario from before, if you either take supplemental forms or if your body is making beta-hydroxybutyrate, it is able to start processing in your body resulting in energy.
    Where to Buy Lean time keto pill reviews?
    Click Here to More>>>> http://nutrafame.com/
    https://www.facebook.com/Lean-time-keto-Shark-tank-104005228745537
    https://nutrafame.com/2021/10/19/keto-strong-weightloss-formula-for-united-states/
    https://groups.google.com/g/lean-time-keto-us/c/ymgWTzDCc2s
    https://promosimple.com/giveaways/lean-time-keto-lose-weight-correctly-100-bhb-keto-supplement-pill/
    https://promosimple.com/giveaways/lean-time-keto-reviews-or-scam-alert/
    https://promosimple.com/giveaways/lean-time-keto-1-trends-weight-loss-supplement-formula/
    https://dribbble.com/leantimeketodietpills/about
    https://www.spreaker.com/show/lean-time-keto-sharktank-100-legit-pill
    https://www.spreaker.com/user/15488240
    https://besthealthypills.blogspot.com/2021/10/lean-time-keto-reviews-is-it-real-lean.html
    https://www.inkitt.com/leantimeketodietpills
    https://www.stageit.com/leantimeketo
    https://dribbble.com/shots/16701143-LEAN-TIME-KETO-REVIEWS-LEAN-TIME-KETO-DIET-PILLS-SCAM-OR-LEGIT
    https://leantimeketodietpillsreallegit.tumblr.com/
    https://www.completefoods.co/diy/recipes/lean-time-keto-reviews-is-lean-time-keto-diet-pills-scam-or-100-legit-ingredients-buy-now
    https://www.youtube.com/watch?v=3WEhxssXwQc
    https://kit.co/leantimeketodietpill
    https://ethicseducationforchildren.org/fr/discussions/https-www-facebook-com-lean-time-keto-shark-tank-104005228745537
    https://www.letmetalk.info/discussions/https-www-facebook-com-lean-time-keto-shark-tank-104005228745537.html
    https://www.facebook.com/Keto-strong-Canada-101477875662892
    https://www.facebook.com/Keto-Strong-Review-Negative-Side-Effects-or-Extra-Strength-107692011684646
    https://skybounds.com/threads/lean-time-keto-reviews-updated-2021-is-it-another-scam-or-not-its-really-worked.22498/https://medium.com/@healthcarefitnessbrand/lean-time-keto-35ed4110c677
    https://educatorpages.com/site/donnajeboeuf/pages/lean-time-keto-reviews-100-legit-is-it-ripoff-or-safe?
    https://www.homify.in/ideabooks/8359610/lean-time-keto-reviews-100-certified-is-it-safe-or-scam
    https://leantimeketoreviews.mystrikingly.com/

    0 0 Commenti 0 Shares
  • Keto strong Official Website To Buy Now
    BENEFITS OF Keto strong
    Lose Weight
    Burn Fat in Trouble Areas
    Get into Ketosis Fast!*
    Burn Fat for Energy (without the jitters)!
    Better Brain Health!
    HOW DOES IT WORK?
    KETOSIS FORCES YOUR BODY TO BURN FAT FOR ENERGY INSTEAD OF CARBS.
    WHY KETO WORKS!
    Ketosis is the state where your body is actually burning fat for energy instead of carbs. Ketosis is extremely hard to obtain on your own and takes weeks to accomplish. Keto strong pill reviews actually helps your body achieve ketosis fast and helps you burn fat for energy instead of carbs!

    Keto strong pill reviews contains Beta-hydroxybutyrate. BHB is the first substrate that kicks the metabolic state of ketosis into action. Revisiting the scenario from before, if you either take supplemental forms or if your body is making beta-hydroxybutyrate, it is able to start processing in your body resulting in energy.
    Click Here To Visit Our official Websites>>>>>
    https://sites.google.com/view/keto-strong-pill-reviews/home
    https://www.facebook.com/Keto-Strong-Review-Negative-Side-Effects-or-Extra-Strength-107692011684646
    https://nutrafame.com/2021/10/19/keto-strong-weightloss-formula-for-united-states/

    https://www.facebook.com/Keto-strong-Canada-101477875662892
    https://kit.co/ketostrongcanada/keto-strong-canada
    https://groups.google.com/g/keto-strong-reviews---scam-or-are-ketostrong-diet-pills-legit/c/azO-6TZuBKg
    https://www.spreaker.com/user/15380140
    https://www.spreaker.com/show/keto-strong-pill-reviews-100-legit
    https://www.inkitt.com/Keto_strong_Better_Dieting
    https://issuu.com/donnajeboeuf/docs/keto_strong_diet_pills-converted
    https://kit.co/ketostrong-diet-pills/keto-strong-better-dieting-support
    https://issuu.com/dnnamayugh/docs/keto_strong_diet_pills-converted_1_
    https://issuu.com/dnnamayugh/docs/keto_strong_diet_pills-converted_1_/s/13579611
    https://www.completefoods.co/diy/recipes/keto-strong-pills-reviews-how-does-it-work-or-scam-2021
    https://www.homify.in/projects/1047910/keto-strong-pill-reviews
    https://www.completefoods.co/diy/recipes/keto-strong-pill-reviews
    https://www.homify.in/projects/1047923/keto-strong-reviews-scam-or-are-ketostrong-diet-pills-legit
    https://www.kemovebbs.com/Thread-BENEFITS-OF-KETO-STRONG-PILLS
    https://www.completefoods.co/diy/recipes/keto-strong-pills-reviews-how-does-it-work-or-scam-2021
    https://www.facebook.com/Keto-strong-pill-reviews-111083061340508
    https://www.kemovebbs.com/Thread-BENEFITS-OF-KETO-STRONG-PILLS
    https://www.weddingwire.com/wedding-forums/benefits-of-keto-strong-pills/8a4840eb1bd07bcf.html
    https://www.instagram.com/ketostrongpillreviews/
    https://twitter.com/StrongPill
    https://www.facebook.com/Keto-Strong-Review-Negative-Side-Effects-or-Extra-Strength-107692011684646
    https://keto-strong-pill-reviews-1.jimdosite.com/
    https://ketostrongpillreviewsus.tumblr.com/
    https://promosimple.com/giveaways/keto-srong-diet-pills-reviews-benefits-or-not-a-scam/
    https://promosimple.com/giveaways/keto-strong-pills-ingredents/
    https://nutrafame.com/2021/10/19/keto-strong-weightloss-formula-for-united-states/
    https://www.kemovebbs.com/Thread-Keto-Strong-Reviews-%E2%80%93-Serious-Scam-Pill-Dangers-or-Is-It-100-Legit
    https://promosimple.com/giveaways/keto-strong-reviews-scam-risk-fake-side-effects-shocking-price-shark-tank-buy-us/


    https://issuu.com/phyllismitcham/docs/keto_strong_usa_best_keto_diet_pills_really_worked
    https://dribbble.com/strongdiet/about

    0 0 Commenti 0 Shares
  • The prefilled syringe fill / finish services market is projected to grow at an annualized rate of over 10%, till 2030
    Roots Analysis has done a detailed study on Prefilled Syringe Fill / Finish Services Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

    To order this 260+ page report, which features 60+ figures and 110+ tables, please visit Prefilled Syringe Fill / Finish Services Market, 2020-2030

    Key Market Insights
     Over 100 companies across the globe claim to provide contract fill / finish services for prefilled syringes; close to 50% of these service providers are large companies with over 500 employees.
     The market landscape features the presence of well- established players in the domain, most of which claim to operate at various scales of operation and are located in different geographies.
     In order to acquire competencies across the supply chain and cater to the evolving needs of clients, companies offering services across different scales of operation have established presence in various geographies.
     Fill / finish service providers are actively investing in expansion projects to upgrade existing capabilities and capacity; several partnerships, mostly focused on offering contract services, have also been forged.
     As expected, majority of the installed contract fill / finish capacity for prefilled syringes belongs to the large service providers, accounting for around 80% of the available global capacity.
     The demand for fill / finish services for prefilled syringes is likely to steadily increase in the coming years; we believe stakeholders may have to expand their respective capacities to ensure a consistent supply.
     An evaluation of prefilled syringe combination product developers revealed that Europe and North America have emerged as the key regions for partnering opportunities for fill / finish service providers.
     Caste Study: Around 70 prefilled syringes are being manufactured by large companies, most of which claim to be capable of fabricating syringe barrels from both glass and plastic materials.
     We expect drug developers to continue to outsource their fill / finish operations in the short to mid term, resulting in an annualized growth at the rate of over 8% within the contract services market.
     In the long-term, the projected opportunity for the fill / finish service providers for prefilled syringes is likely to be well distributed across various types of barrel chambers, scales of operation and geographical regions.

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/prefilled-syringe-fill-finish-services/301.html

    Table of Contents

    1. PREFACE
    1.1. Chapter Overview
    1.2. Scope of the Report
    1.3. Research Methodology
    1.4. Chapter Outlines

    2. EXECUTIVE SUMMARY

    3. INTRODUCTION
    3.1. Chapter Overview
    3.2. Introduction to Prefilled Syringes
    3.2.1. Classification of Prefilled Syringes
    3.2.2. Manufacturing of Prefilled Syringes
    3.2.3. Advantages of Prefilled Syringes
    3.2.3.1. Benefits to Healthcare Professionals and End Users
    3.2.3.2. Benefits to Manufacturers

    3.3. Fill / Finish Processing of Prefilled Syringes
    3.3.1. Steps Involved in Fill / Finish Process
    3.3.2. Methods of Filling and Stoppering of Prefilled Syringes
    3.3.3. Prefilled Syringe Filling Technologies

    3.4. Factors Contributing to the Growth of Prefilled Syringe Fill / Finish Market
    3.5. Need for Outsourcing Fill / Finish Operations of Sterile Injectables
    3.6. Advantages of Outsourcing Fill / Finish Services
    3.7. Risks Associated with Outsourcing of Fill / Finish Operations
    3.8. Key Considerations While Selecting a Fill / Finish Service Provider

    4. MARKET LANDSCAPE
    4.1. Chapter Overview
    4.2. Prefilled Syringe Fill / Finish Service Providers: Overall Market Landscape
    4.2.1. Analysis by Year of Establishment
    4.2.2. Analysis by Company Size
    4.2.3. Analysis by Scale of Operation
    4.2.4. Analysis by Location of Headquarters
    4.2.5. Analysis by Location of Prefilled Syringe Fill / Finish Facilities
    4.2.6. Analysis by Type of Drug Molecule
    4.2.7. Analysis by Syringe Barrel Material
    4.2.8. Analysis by Syringe Fill Volume
    4.2.9. Analysis by Additional Services Offered
    4.2.10. Heat Map: Analysis by Company Size and Location of Headquarters
    4.2.11. Logo Landscape: Analysis by Company Size and Type of Drug Molecule
    4.2.12. Geographical Map: Analysis by Scale of Operation and Location of Fill / Finish Facilities
    4.2.13. Grid Representation: Distribution by Year of Establishment, Company Size and Type of Drug Molecule

    5. PREFILLED SYRINGE FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES
    5.1. Chapter Overview
    5.2. Ajinomoto Bio-Pharma Services
    5.2.1. Company Overview
    5.2.2. Recent Developments and Future Outlook

    5.3. AMRI
    5.3.1. Company Overview
    5.3.2. Recent Developments and Future Outlook

    5.4. BioPharma Solutions
    5.4.1. Company Overview
    5.4.2. Recent Developments and Future Outlook

    5.5. Emergent BioSolutions
    5.5.1. Company Overview
    5.5.2. Recent Developments and Future Outlook

    5.6. Patheon (a Thermo Fisher Scientific Company)
    5.6.1. Company Overview
    5.6.2. Recent Developments and Future Outlook



    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Gaurav Chaudhary
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis

    Prefilled Syringe Fill / Finish Services | Industry Analysis | Market Size | 2030
    Market research report on prefilled syringe (PFS) fill / finish services; with a focus on current market landscape and future growth opportunities
    WWW.ROOTSANALYSIS.COM
    0 0 Commenti 0 Shares
  • The synthetic lethality-based drugs and targets market is projected to grow at an annualized rate of ~18%, till 2030
    Roots Analysis has done a detailed study on “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

    To order this 485+ page report, which features 195+ figures and 200+ tables, please visit Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways

    Key Market Insights
     An analysis of recent activity on Twitter confirms the rising interest in this domain as stakeholders attempt to harness the therapeutic potential of synthetic lethality
     About 75 drug candidates based on synlet gene pairs are being evaluated for the treatment of various types of cancers; presently, there are over 20 screening platforms enabling therapy development efforts
     The pipeline features both small molecules and biologic drugs based on different synlet targets for treating a variety of oncological and non-oncological indications
     Innovation in this domain is evident across the plethora of scientific articles published in prestigious journals, highlighting key focus areas and prevalent / upcoming trends
     Over time, several non-profit organizations have extended financial support to aid research efforts in this domain; the current focus appears to be on the identification of novel synlet targets across different clinical conditions
     Significant advances in research have led to the discovery of a wide array of synlet targets; over time, substantial intellectual capital has been generated and validated by eminent scientists from renowned research institutes
     To support innovation, several private and public investors have made substantial capital investments, totalling to approximately USD 5.1 billion, across 100 instances of funding
     The personalized approach offered by companion diagnostics presents enormous opportunities for drug developers to partner with diagnostic test providers to improve patient / subject selection in clinical trials
     Future growth of the market is likely to be driven by the success of clinical outcomes of late-stage molecules; industry stakeholders are optimistic about the vast potential of PARP inhibitors
     In the mid to long term, the anticipated market opportunity is likely to be well distributed across advanced cancer indications, delivery routes and various global regions

    For more information, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html

    Table of Contents

    1. PREFACE
    1.1. Scope of the Report
    1.2. Research Methodology
    1.3. Chapter Outlines

    2. EXECUTIVE SUMMARY

    3. INTRODUCTION TO DNA DAMAGE AND REPAIR SYSTEMS
    3.1. Chapter Overview
    3.2. Overview of Deoxyribonucleic Acid (DNA) Damage
    3.3. DNA Damaging Agents
    3.3.1. Endogenous DNA Damaging Agents
    3.3.2. Exogenous DNA Damaging Agents
    3.3.3. Other DNA Damaging Agents
    3.4. DNA Damage Response System
    3.4.1. Key Components of DNA Repair System

    3.5. Types of DNA Repair Systems
    3.5.1. Direct Repair
    3.5.1.1. Photoreactivation
    3.5.1.2. Alkyl Transferase Mediated Direct DNA Repair
    3.5.1.3. AlkB Mediated Direct DNA Repair
    3.5.1.4. DNA Ligase Mediated Direct DNA Repair

    3.5.2. Excision Repair
    3.5.2.1. Base Excision Repair (BER)
    3.5.2.1.1. BER Pathway: Key Enzymes
    3.5.2.1.1.1. DNA Glycosylases
    3.5.2.1.1.2. Apurinic / Apyrimidinic (AP) Endonucleases
    3.5.2.1.1.3. Other Enzymes
    3.5.2.1.2. Short-Patch Base Excision Repair
    3.5.2.1.3. Long-Patch Base Excision Repair
    3.5.2.2. Nucleotide Excision Repair (NER)
    3.5.2.3. Mismatch Repair

    3.5.3. Indirect Repair
    3.5.3.1. Homologous Recombination Repair (HRR)
    3.5.3.2. Non-Homologous End-Joining

    3.6. Mutations in DNA Repair Genes

    4. INTRODUCTION TO SYNTHETIC LETHALITY
    4.1. Chapter Overview
    4.2. Concept of Synthetic Lethality
    4.2.1. Historical Evolution of Synthetic Lethality
    4.2.2. HRR and Synthetic Lethality
    4.2.3. Other Synthetic Lethal Gene Interactions
    4.2.4. Advantages of Synthetic Lethality
    4.2.5. Limitations of Synthetic Lethality

    4.3. Identification of Synlet Interactions
    4.3.1. Hypothesis-Driven Approach
    4.3.2. Screening-Based Approaches
    4.3.2.1. Chemical Library-Based Screening Approaches
    4.3.2.1.1. Non-Annotated Libraries
    4.3.2.1.2. Annotated Libraries
    4.3.2.2. Genome-Wide Interference-Based Screening Approaches
    4.3.2.2.1. Ribonucleic Acid Interference (RNAi) Based Synlet Target Identification
    4.3.2.2.2. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Based Synlet Target Identification
    4.3.3. In Silico Approaches

    4.4. Prevalent Trends Related to Synthetic Lethality
    4.4.1. Recent News on Google: Emerging Focus Areas
    4.4.2. Google Trends Analysis: Historical Timeline
    4.4.3. Google Trends Analysis: Geographical Activity
    4.4.4. Google Trends Analysis: Other Key Terms Related to Synthetic Lethality

    4.5 Concluding Remarks

    5. MARKET OVERVIEW
    5.1. Chapter Overview
    5.2. Synthetic Lethality-based Drugs: Marketed and Development Pipeline
    5.2.1. Analysis by Phase of Development
    5.2.2. Analysis by Type of Molecule
    5.2.3. Analysis by Type of Therapy
    5.2.4. Analysis by Type of Synlet Target
    5.2.5. Analysis by Therapeutic Area
    5.2.6. Analysis by Target Indication
    5.2.7. Analysis by Patient Segment
    5.2.8. Analysis by Route of Administration

    5.3. Synthetic Lethality-based Drugs: List of Screening Platforms
    5.4 Synthetic Lethality-based Drugs: List of Drug Developers / Screening Platform Providers
    5.4.1. Analysis by Year of Establishment
    5.4.2. Analysis by Location of Headquarters
    5.4.3. Analysis by Company Size
    5.4.4. Analysis by Company Size and Location of Headquarters
    5.4.5. Leading Drug Developers

    6. COMPANY PROFILES
    6.1. Chapter Overview
    6.2. Profiles of Established Players
    6.2.1. AbbVie
    6.2.1.1. Company Overview
    6.2.1.2. Synthetic Lethality-based Drug Portfolio
    6.2.1.2.1. Veliparib (ABT-888)
    6.2.1.3. Recent Developments and Future Outlook

    6.2.2. AstraZeneca
    6.2.2.1. Company Overview
    6.2.2.2. Synthetic Lethality-based Drug Portfolio
    6.2.2.2.1. Olaparib (Lynparza®)
    6.2.2.2.2. AZD6738
    6.2.2.2.3. AZD1775
    6.2.2.3. Recent Developments and Future Outlook

    6.2.3. BeiGene
    6.2.3.1. Company Overview
    6.2.3.2. Synthetic Lethality-based Drug Portfolio
    6.2.3.2.1. Pamiparib (BGB-290)
    6.2.3.3. Recent Developments and Future Outlook

    6.2.4. Clovis Oncology
    6.2.4.1. Company Overview
    6.2.4.2. Synthetic Lethality-based Drug Portfolio
    6.2.4.2.1. Rucaparib (Rubraca®)
    6.2.4.3. Recent Developments and Future Outlook

    6.2.5. GlaxoSmithKline
    6.2.5.1. Company Overview
    6.2.5.2. Synthetic Lethality-based Drug Portfolio
    6.2.5.2.1. Niraparib (Zejula®)
    6.2.5.3. Recent Developments and Future Outlook

    6.2.6. Pfizer
    6.2.6.1. Company Overview
    6.2.6.2. Synthetic Lethality-based Drug Portfolio
    6.2.6.2.1. Talazoparib (TALZENNA®)
    6.2.6.3. Recent Developments and Future Outlook

    6.3. Profiles of Small and Mid-Sized Players
    6.3.1. AtlasMedx
    6.3.2. Chordia Therapeutics
    6.3.3. IDEAYA Biosciences
    6.3.4. Mission Therapeutics
    6.3.5. Repare Therapeutics
    6.3.6. Sierra Oncology
    6.3.7. SyntheX Labs

    7. EMERGING TRENDS ON SOCIAL MEDIA
    7.1. Chapter Overview
    7.2. Scope and Methodology
    7.3. Synthetic Lethality: Trends on Twitter
    7.3.1. Cumulative Year-Wise Activity
    7.3.2. Historical Trends in Volume of Tweets
    7.3.3. Evolutionary Trend Analysis
    7.3.4. Trending Words / Phrases on Twitter
    7.3.5. Most Prolific Contributors on Twitter
    7.3.6. Most Popular Synlet Targets / Patient Mutations on Twitter
    7.3.7. Most Popular Indications on Twitter
    7.3.8. Heat Map Analysis: Distribution by Synlet Targets / Patient Mutations and Indications

    7.4. Most Popular Tweets
    7.5. Concluding Remarks

    8. PUBLICATION ANALYSIS
    8.1. Chapter Overview
    8.2. Scope and Methodology

    8.3. Synthetic Lethality: List of Recent Publications, 2019
    8.3.1. Analysis by Type of Publication
    8.3.2. Analysis by Study Objective

    8.4. Synthetic Lethality: Publication Analysis, 2017–2019
    8.4.1. Analysis by Year of Publication

    8.4.2. Emerging Focus Areas
    8.4.3. Analysis by Synlet Targets / Patient Mutations
    8.4.3.1. Most Popular Synlet Targets / Patient Mutations
    8.4.3.2. Year-Wise Trend in Activity for Popular Synlet Targets / Patient Mutations
    8.4.4. Analysis by Target Indications
    8.4.4.1. Most Popular Target Indications
    8.4.4.2. Year-Wise Trend in Activity for Popular Target Indications

    8.4.5. Analysis by Key Research Journals
    8.4.5.1. Key Journals Based on Number of Publications
    8.4.5.2. Analysis by Journal Impact Factor
    8.4.5.3. Key Journals Based on Journal Impact Factor

    8.4.6. Key Research Hubs
    8.4.7. Most Popular Authors

    8.4.8. Analysis of Publications with Grant Support
    8.4.8.1. Most Popular Grant Bodies
    8.4.8.2. Location of Grant Bodies

    8.5. Publication Benchmark Analysis

    9. ABSTRACT ANALYSIS
    9.1. Chapter Overview
    9.2. Scope and Methodology

    9.3. Synthetic Lethality: List of American Society of Clinical Oncology Abstracts
    9.3.1. Analysis by Year of Publication
    9.3.2. Emerging Focus Areas
    9.3.3. Most Popular Drugs
    9.3.4. Most Popular Synlet Targets / Patient Mutations
    9.3.5. Most Popular Target Indications
    9.3.6. Most Popular Principal Authors
    9.3.6.1. Analysis by Locations of Principal Authors
    9.3.6.2. Analysis by Type of Organization of Principal Authors
    9.3.6.3. Analysis by Active Organization
    9.3.6.4. Analysis by Author Designation
    9.3.6.5. Most Popular Authors

    10. ACADEMIC GRANTS ANALYSIS
    10.1. Chapter Overview
    10.2. Scope and Methodology

    10.3. Synthetic Lethality: List of Grants Awarded by National Institutes of Health
    10.3.1. Analysis by Year of Award
    10.3.2. Analysis by Amount Awarded
    10.3.3. Analysis by Administering Institute Center
    10.3.4. Analysis by Funding Institute Center
    10.3.5. Analysis by Support Period
    10.3.6. Analysis by Funding Institute Center and Support Period
    10.3.7. Most Popular National Institute of Health (NIH) Funding Categorization
    10.3.8. Analysis by Funding Mechanism
    10.3.9. Analysis by Emerging Focus Areas
    10.3.10. Most Popular Synlet Targets / Patient Mutations
    10.3.11. Most Popular Target Indications
    10.3.12. Analysis by Type of Grant Application
    10.3.13. Most Popular NIH Departments
    10.3.14. Analysis by Study Section
    10.3.15. Analysis by Type of Recipient Organization
    10.3.16. Most Popular Recipient Organization
    10.3.17. Most Popular Recipient Organization and NIH Spending Sectors
    10.3.18. Analysis by Grant Activity
    10.3.19. Most Prominent Program Officers
    10.3.20. Regional Distribution of Recipient Organization

    10.4. Grant Attractiveness Analysis

    11. FUNDING AND INVESTMENT ANALYSIS
    11.1. Chapter Overview
    11.2. Types of Funding

    11.3. Synthetic Lethality: List of Funding and Investments
    11.3.1. Analysis by Number of Instances
    11.3.2. Analysis by Amount Invested
    11.3.3. Analysis by Type of Funding
    11.3.4. Analysis by Type of Company
    11.3.5. Analysis by Purpose of Funding
    11.3.6. Analysis by Type of Molecule
    11.3.7. Analysis by Synlet Target
    11.3.8. Analysis by Therapeutic Area
    11.3.9. Analysis by Target Indication
    11.3.10. Analysis by Geography
    11.3.11. Most Active Players
    11.3.12. Most Active Investors

    11.4. Concluding Remarks

    12. TARGET BENCHMARK ANALYSIS
    12.1. Chapter Overview
    12.2. Scope and Methodology
    12.3. Target Benchmark Analysis
    12.3.1. Clinically Validated Synlet Targets
    12.3.2. Preclinically Validated Synlet Targets
    12.3.3. Early Stage Research Validated Synlet Targets
    12.4. Initiatives of Big Pharmaceutical Players
    12.5. Concluding Remarks

    13. ROLE OF COMPANION DIAGNOSTICS IN SYNTHETIC LETHALITY
    13.1. Chapter Overview
    13.2. Concept of Companion Diagnostics
    13.3. Development of Companion Diagnostics
    13.3.1. Co-development / Parallel Development Approach
    13.3.2. Development of Companion Diagnostics Post Drug Approval
    13.3.3. Development of already Approved Companion Diagnostics for New Drugs / Disease Indications

    13.4. Advantages of Companion Diagnostics
    13.5. Applications of Companion Diagnostics in Synthetic Lethality

    13.6. Companion Diagnostics: List of Available / Under Development Tests
    13.6.1. Analysis by Synlet Target
    13.6.2. Analysis by Type of Biomarker
    13.6.3. Analysis by Type of Biomarker and Technology
    13.6.4. Analysis by Target Indication
    13.6.5. Analysis by Developer and Synlet Target
    13.6.6. Most Prominent Developers

    13.7. Case-in-Point: Companion Diagnostics for Commercially Available Poly-ADP Ribose Polymerase (PARP) Inhibitors
    13.7.1. Companion Diagnostics Test for Niraparib
    13.7.1.1. Product Overview
    13.7.1.2. Working Process
    13.7.1.3. Collaborations

    13.7.2. Companion Diagnostics Test for Olaparib
    13.7.2.1. Product Overview
    13.7.2.2. Working Process
    13.7.2.3. Collaborations

    13.7.3. Companion Diagnostics Test for Rucaparib
    13.7.3.1. Product Overview
    13.7.3.2. Collaborations

    13.7.4. Companion Diagnostics Test for Talazoparib
    13.7.4.1. Product Overview
    13.7.4.2. Collaborations

    13.8. Future Perspective

    14. MARKET FORECAST
    14.1. Chapter Overview
    14.2. Scope and Limitations
    14.3. Forecast Methodology and Key Assumptions

    14.4. Overall Synthetic Lethality-based Drugs Market, 2019-2030
    14.4.1. Synthetic Lethality-based Drugs Market: Distribution by Type of Molecule, 2019 and 2030
    14.4.1.1. Synthetic Lethality-based Drugs Market for Small Molecule, 2019-2030
    14.4.1.2. Synthetic Lethality-based Drugs Market for Biologic, 2019-2030

    14.4.2. Synthetic Lethality-based Drugs Market: Distribution by Synlet Target, 2019 and 2030
    14.4.2.1. Synthetic Lethality-based Drugs Market for APE1 / REF-1, 2019-2030
    14.4.2.2. Synthetic Lethality-based Drugs Market for CHK1, 2019-2030
    14.4.2.3. Synthetic Lethality-based Drugs Market for GLS1, 2019-2030
    14.4.2.4. Synthetic Lethality-based Drugs Market for PARP, 2019-2030
    14.4.2.5. Synthetic Lethality-based Drugs Market for Polθ, 2019-2030
    14.4.2.6. Synthetic Lethality-based Drugs Market for WEE1, 2019-2030

    14.4.3. Synthetic Lethality-based Drugs Market: Distribution by Target Indication, 2019 and 2030
    14.4.3.1. Synthetic Lethality-based Drugs Market for Breast Cancer, 2019-2030
    14.4.3.2. Synthetic Lethality-based Drugs Market for Cervical / Anogenital Cancer, 2019-2030
    14.4.3.3. Synthetic Lethality-based Drugs Market for Diabetic Macular Edema, 2019-2030
    14.4.3.4. Synthetic Lethality-based Drugs Market for Gastric Cancer, 2019-2030
    14.4.3.5. Synthetic Lethality-based Drugs Market for Lung Cancer, 2019-2030
    14.4.3.5. Synthetic Lethality-based Drugs Market for Ovarian Cancer, 2019-2030
    14.4.3.7. Synthetic Lethality-based Drugs Market for Renal Cell Cancer, 2019-2030

    14.4.4. Synthetic Lethality-based Drugs Market: Distribution by Route of Administration, 2019 and 2030
    14.4.4.1. Synthetic Lethality-based Drugs Market for Oral Therapies, 2019-2030
    14.4.4.2. Synthetic Lethality-based Drugs Market for Intravenous Therapies, 2019-2030

    14.4.5. Synthetic Lethality-based Drugs Market: Distribution by Geography, 2019 and 2030
    14.4.5.1. Synthetic Lethality-based Drugs Market in the US, 2019-2030
    14.4.5.2. Synthetic Lethality-based Drugs Market in France, 2019-2030
    14.4.5.3. Synthetic Lethality-based Drugs Market in Germany, 2019-2030
    14.4.5.4. Synthetic Lethality-based Drugs Market in Italy, 2019-2030
    14.4.5.5. Synthetic Lethality-based Drugs Market in Spain, 2019-2030
    14.4.5.6. Synthetic Lethality-based Drugs Market in the UK, 2019-2030
    14.4.5.8. Synthetic Lethality-based Drugs Market in Australia, 2019-2030
    14.4.5.7. Synthetic Lethality-based Drugs Market in China, 2019-2030
    14.4.5.8. Synthetic Lethality-based Drugs Market in Japan, 2019-2030

    14.4.6. Product-wise Sales Forecast
    14.4.6.1 Niraparib (GlaxoSmithKline)
    14.4.6.1.1. Target Patient Population
    14.4.6.1.2. Sales Forecast (USD Million)
    14.4.6.1.3. Net Present Value (USD Million)
    14.4.6.1.4. Value Creation Analysis

    14.4.6.2. Olaparib (AstraZeneca)
    14.4.6.2.1. Target Patient Population
    14.4.6.2.2. Sales Forecast (USD Million)
    14.4.6.2.3. Net Present Value (USD Million)
    14.4.6.2.4. Value Creation Analysis

    14.4.6.3. Rucaparib (Clovis Oncology)
    14.4.6.3.1. Target Patient Population
    14.4.6.3.2. Sales Forecast (USD Million)
    14.4.6.3.3. Net Present Value (USD Million)
    14.4.6.3.4. Value Creation Analysis

    14.4.6.4. Talazoparib (Pfizer)
    14.4.6.4.1. Target Patient Population
    14.4.6.4.2. Sales Forecast (USD Million)
    14.4.6.4.3. Net Present Value (USD Million)
    14.4.6.4.4. Value Creation Analysis

    14.4.6.5. Pamiparib (BeiGene)
    14.4.6.5.1. Target Patient Population
    14.4.6.5.2. Sales Forecast (USD Million)
    14.4.6.5.3. Net Present Value (USD Million)
    14.4.6.5.4. Value Creation Analysis

    14.4.6.6. Veliparib (AbbVie)
    14.4.6.6.1. Target Patient Population
    14.4.6.6.2. Sales Forecast (USD Million)
    14.4.6.6.3. Net Present Value (USD Million)
    14.4.6.6.4. Value Creation Analysis

    14.4.6.7. Adavosertib (AstraZeneca)
    14.4.6.7.1. Target Patient Population
    14.4.6.7.2. Sales Forecast (USD Million)
    14.4.6.7.3. Net Present Value (USD Million)
    14.4.6.7.4. Value Creation Analysis

    14.4.6.8. APX3330 (Apexian Pharmaceuticals)
    14.4.6.8.1. Target Patient Population
    14.4.6.8.2. Sales Forecast (USD Million)
    14.4.6.8.3. Net Present Value (USD Million)
    14.4.6.8.4. Value Creation Analysis

    14.4.6.9. CX-5461 (Senhwa Biosciences)
    14.4.6.9.1. Target Patient Population
    14.4.6.9.2. Sales Forecast (USD Million)
    14.4.6.9.3. Net Present Value (USD Million)
    14.4.6.9.4. Value Creation Analysis

    14.4.6.10. SRA737-01 (Sierra Oncology)
    14.4.6.10.1. Target Patient Population
    14.4.6.10.2. Sales Forecast (USD Million)
    14.4.6.10.3. Net Present Value (USD Million)
    14.4.6.10.4. Value Creation Analysis

    14.4.6.11. SRA737-02 (Sierra Oncology)
    14.4.6.11.1. Target Patient Population
    14.4.6.11.2. Sales Forecast (USD Million)
    14.4.6.11.3. Net Present Value (USD Million)
    14.4.6.11.4. Value Creation Analysis

    14.4.6.12. Telaglenastat (Calithera Biosciences)
    14.4.6.12.1. Target Patient Population
    14.4.6.12.2. Sales Forecast (USD Million)
    14.4.6.12.3. Net Present Value (USD Million)
    14.4.6.12.4. Value Creation Analysis

    14.4.7. Concluding Remarks

    15. CONCLUDING REMARKS

    16. EXECUTIVE INSIGHTS
    16.1. Chapter Overview
    16.2. Artios Pharma
    16.2.1. Company / Organization Snapshot
    16.2.2. Interview Transcript: Simon Boulton, Vice President, Science Strategy

    16.3. IMPACT Therapeutics
    16.3.1. Company / Organization Snapshot
    16.3.2. Interview Transcript: Yi Xu, Associate Director

    16.4. Harvard Medical School
    16.4.1. Company / Organization Snapshot
    16.4.2. Interview Transcript: Norbert Perrimon, Professor, Department of Genetics

    16.5. Panjab University
    16.5.1. Company / Organization Snapshot
    16.5.2. Interview Transcript: Vivek Dharwal, Professor, Department of Biochemistry

    16.6. UbiQ
    16.6.1. Company / Organization Snapshot
    16.6.2. Interview Transcript: Alfred Nijkerk, Chief Executive Officer

    17. APPENDIX 1: TABULATED DATA

    18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Gaurav Chaudhary
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis

    Synthetic Lethality-based Drugs: Focus on DNA Repair (PARP Inhibitors) | Industry Analysis | Market Size | 2030
    Synthetic Lethality-based Drugs (DNA repair, parp inhibitors, brca gene mutation, pi3k inhibitor and others) Market is Poised to Witness a Rapid Growth
    WWW.ROOTSANALYSIS.COM
    0 0 Commenti 0 Shares
  • Keto strong Official Website To Buy Now
    BENEFITS OF Keto strong
    Lose Weight
    Burn Fat in Trouble Areas
    Get into Ketosis Fast!*
    Burn Fat for Energy (without the jitters)!
    Better Brain Health!
    HOW DOES IT WORK?
    KETOSIS FORCES YOUR BODY TO BURN FAT FOR ENERGY INSTEAD OF CARBS.
    WHY KETO WORKS!
    Ketosis is the state where your body is actually burning fat for energy instead of carbs. Ketosis is extremely hard to obtain on your own and takes weeks to accomplish. Keto strong pill reviews actually helps your body achieve ketosis fast and helps you burn fat for energy instead of carbs!

    Keto strong pill reviews contains Beta-hydroxybutyrate. BHB is the first substrate that kicks the metabolic state of ketosis into action. Revisiting the scenario from before, if you either take supplemental forms or if your body is making beta-hydroxybutyrate, it is able to start processing in your body resulting in energy.
    Click Here To Visit Our official Websites>>>>>
    https://sites.google.com/view/keto-strong-pill-reviews/home
    https://www.facebook.com/Keto-Strong-Review-Negative-Side-Effects-or-Extra-Strength-107692011684646
    https://www.facebook.com/Keto-strong-Canada-101477875662892
    https://kit.co/ketostrongcanada/keto-strong-canada
    https://groups.google.com/g/keto-strong-reviews---scam-or-are-ketostrong-diet-pills-legit/c/azO-6TZuBKg
    https://www.spreaker.com/user/15380140
    https://www.spreaker.com/show/keto-strong-pill-reviews-100-legit
    https://www.inkitt.com/Keto_strong_Better_Dieting
    https://issuu.com/donnajeboeuf/docs/keto_strong_diet_pills-converted
    https://kit.co/ketostrong-diet-pills/keto-strong-better-dieting-support
    https://issuu.com/dnnamayugh/docs/keto_strong_diet_pills-converted_1_
    https://issuu.com/dnnamayugh/docs/keto_strong_diet_pills-converted_1_/s/13579611
    https://www.completefoods.co/diy/recipes/keto-strong-pills-reviews-how-does-it-work-or-scam-2021
    https://www.homify.in/projects/1047910/keto-strong-pill-reviews
    https://www.completefoods.co/diy/recipes/keto-strong-pill-reviews
    https://www.homify.in/projects/1047923/keto-strong-reviews-scam-or-are-ketostrong-diet-pills-legit
    https://www.kemovebbs.com/Thread-BENEFITS-OF-KETO-STRONG-PILLS
    https://www.completefoods.co/diy/recipes/keto-strong-pills-reviews-how-does-it-work-or-scam-2021
    https://www.facebook.com/Keto-strong-pill-reviews-111083061340508
    https://www.kemovebbs.com/Thread-BENEFITS-OF-KETO-STRONG-PILLS
    https://www.weddingwire.com/wedding-forums/benefits-of-keto-strong-pills/8a4840eb1bd07bcf.html
    https://www.instagram.com/ketostrongpillreviews/
    https://twitter.com/StrongPill
    https://www.facebook.com/Keto-Strong-Review-Negative-Side-Effects-or-Extra-Strength-107692011684646
    https://keto-strong-pill-reviews-1.jimdosite.com/
    https://ketostrongpillreviewsus.tumblr.com/
    https://promosimple.com/giveaways/keto-srong-diet-pills-reviews-benefits-or-not-a-scam/
    https://promosimple.com/giveaways/keto-strong-pills-ingredents/
    https://promosimple.com/giveaways/keto-strongus-official-website-to-buy-now/

    Keto strong
    Keto strong
    SITES.GOOGLE.COM
    0 0 Commenti 0 Shares
  • Keto strong Official Website To Buy Now
    BENEFITS OF Keto strong
    Lose Weight
    Burn Fat in Trouble Areas
    Get into Ketosis Fast!*
    Burn Fat for Energy (without the jitters)!
    Better Brain Health!
    HOW DOES IT WORK?
    KETOSIS FORCES YOUR BODY TO BURN FAT FOR ENERGY INSTEAD OF CARBS.
    WHY KETO WORKS!
    Ketosis is the state where your body is actually burning fat for energy instead of carbs. Ketosis is extremely hard to obtain on your own and takes weeks to accomplish. Keto strong pill reviews actually helps your body achieve ketosis fast and helps you burn fat for energy instead of carbs!

    Keto strong pill reviews contains Beta-hydroxybutyrate. BHB is the first substrate that kicks the metabolic state of ketosis into action. Revisiting the scenario from before, if you either take supplemental forms or if your body is making beta-hydroxybutyrate, it is able to start processing in your body resulting in energy.
    Click Here To Visit Our official Websites>>>>>
    https://sites.google.com/view/keto-strong-pill-reviews/home
    https://www.facebook.com/Keto-Strong-Review-Negative-Side-Effects-or-Extra-Strength-107692011684646
    https://www.facebook.com/Keto-strong-Canada-101477875662892
    https://kit.co/ketostrongcanada/keto-strong-canada
    https://groups.google.com/g/keto-strong-reviews---scam-or-are-ketostrong-diet-pills-legit/c/azO-6TZuBKg
    https://www.spreaker.com/user/15380140
    https://www.spreaker.com/show/keto-strong-pill-reviews-100-legit
    https://www.inkitt.com/Keto_strong_Better_Dieting
    https://issuu.com/donnajeboeuf/docs/keto_strong_diet_pills-converted
    https://kit.co/ketostrong-diet-pills/keto-strong-better-dieting-support
    https://issuu.com/dnnamayugh/docs/keto_strong_diet_pills-converted_1_
    https://issuu.com/dnnamayugh/docs/keto_strong_diet_pills-converted_1_/s/13579611
    https://www.completefoods.co/diy/recipes/keto-strong-pills-reviews-how-does-it-work-or-scam-2021
    https://www.homify.in/projects/1047910/keto-strong-pill-reviews
    https://www.completefoods.co/diy/recipes/keto-strong-pill-reviews
    https://www.homify.in/projects/1047923/keto-strong-reviews-scam-or-are-ketostrong-diet-pills-legit
    https://www.kemovebbs.com/Thread-BENEFITS-OF-KETO-STRONG-PILLS
    https://www.completefoods.co/diy/recipes/keto-strong-pills-reviews-how-does-it-work-or-scam-2021
    https://www.facebook.com/Keto-strong-pill-reviews-111083061340508
    https://www.kemovebbs.com/Thread-BENEFITS-OF-KETO-STRONG-PILLS
    https://www.weddingwire.com/wedding-forums/benefits-of-keto-strong-pills/8a4840eb1bd07bcf.html
    https://www.instagram.com/ketostrongpillreviews/
    https://twitter.com/StrongPill
    https://www.facebook.com/Keto-Strong-Review-Negative-Side-Effects-or-Extra-Strength-107692011684646
    https://keto-strong-pill-reviews-1.jimdosite.com/
    https://ketostrongpillreviewsus.tumblr.com/
    https://promosimple.com/giveaways/keto-srong-diet-pills-reviews-benefits-or-not-a-scam/
    https://promosimple.com/giveaways/keto-strong-pills-ingredents/
    https://promosimple.com/giveaways/keto-strongus-official-website-to-buy-now/

    0 0 Commenti 0 Shares
  • The global handheld ultrasound imaging devices market is projected to be over USD 1.1 billion by 2030

    The increasing medical diagnostic imaging burden has compelled industry players to develop advanced handheld ultrasound scanners that will enable physicians to accurately visualize all major organ systems for diagnostic purposes

    Roots Analysis has announced the addition of “Global Handheld Ultrasound Imaging Devices Market, 2020-2030” report to its list of offerings.

    According to industry experts, handheld ultrasound imaging devices are being adopted at a faster pace by different end-users owing to their higher efficiency and wider applicability. Further, these devices have proven to be useful in quarantining patients demonstrating symptoms of pleural wall thickening and lung congestion, a characteristic of pneumonia, as well as observed in patients suffering from the novel coronavirus (COVID-19).

    To order this 235+ page report, which features 95+ figures and 110+ tables, please visit Global Handheld Ultrasound Imaging Devices Market, 2020-2030

    Key Market Insights

    Nearly 100 handheld ultrasound imaging devices are presently available / under development
    Close to 85% of the aforementioned scanners use linear and curved / convex transducer arrays. Further, to offer variations in image visualization, about 46% of these devices support more than two modes of imaging, including brightness mode (B-mode), color doppler, motion mode (M-mode), pulsed wave, power doppler and tissue harmonic mode.

    70% of scanners are based on smartphone applications
    Handheld devices using abovementioned type of software are primarily being used for gynecology / obstetrics (32%), urological (21%) and abdomen (12%) scanning. It is worth mentioning that customized software-based scanners are preferred in emergency medicines and hospital operating rooms, owing to their ease of handling .

    Partnership activity has grown at an annualized rate of nearly 43%, between 2016 and 2019
    Majority of the collaborations signed in this domain were reported to be distribution and supply agreements (over 30%). In addition, key value drivers in majority of the agreements were expansion of market reach and incorporation of advanced features in devices.

    Demand for handheld ultrasound scanners is anticipated to grow at a CAGR of 12.1%, between 2020 and 2030
    Presently, over 80,000 units of handheld ultrasound scanners are estimated to be used for diagnostic imaging purpose by physicians. In fact, scanners offered by Butterfly Network, Clarius Mobile Health, Fujifilm, GE Healthcare, Siemens Healthineers and Philips are estimated to cater to more than 80% of the current demand for such devices.

    Handheld ultrasound scanners are estimated to enhance radiologists’ efficiency by ~10%
    Owing to their light-weight, portability and advanced imaging features, these devices allow radiologists to perform more number of scans (as compared to conventional stationary devices) in a single day. In fact, by 2030, we anticipate net annual cost savings of over USD 30 billion to be brought about by the adoption of handheld ultrasound scanners.

    By 2030, North America and Europe are anticipated to capture over 70% of the market opportunity
    The market in European regions is anticipated to grow at a relatively faster rate (12.2%). In terms of end-users, by 2030, hospitals are likely to represent the largest share of the market, followed by ambulatory surgical centers (25%) and specialty clinics (16%).

    To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/319/request-sample.html

    Key Questions Answered
     Who are the leading developers of handheld ultrasound imaging devices?
     What are the key application areas for handheld ultrasound imaging scanners?
     What is the potential usability of handheld ultrasound scanners devices for lung scanning in COVID-19 patients?
     Which partnership models are commonly adopted by stakeholders in this industry?
     What is the annual global demand for handheld ultrasound imaging devices?
     What is the impact of COVID-19 on the demand for handheld ultrasound imaging devices?
     What is the likely cost saving potential associated with the use of handheld ultrasound imaging devices?
     What are the key factors influencing the adoption of handheld ultrasound imaging scanners, among different end-users?
     How is the current and future opportunity likely to be distributed across key market segments?

    The USD 1.1 billion (by 2030) financial opportunity within the handheld ultrasound imaging devices market has been analyzed across the following segments:
     Application Area
     Cardiac Scanning
     Emergency Medicines
     Gynecological / Obstetrics Scanning
     Musculoskeletal Scanning
     Pulmonary Scanning
     Urological Scanning
     Vascular Surgery
     Other Application Areas

     Type of Transducer Array
     Curved
     Endocavity
     Linear
     Phased
     Other Scanners

     Type of Software
     Smartphone Applications
     Customized Software

     End-Users
     Ambulatory Surgical Centers
     Diagnostic Imaging Centers
     Hospitals
     Maternity Clinics
     Specialty Clinics
     Other End-Users

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific and the Rest of the World
    The report features inputs from eminent industry stakeholders, according to whom handheld ultrasound imaging devices are likely to offer lucrative market opportunities for players working in this domain. The report includes detailed transcripts of the discussions held with following industry experts:
     Stefan Maas (Chief Executive Officer, SomaView)
     Anais Concepcion (Director of Content and Campaign Management, EchoNous)
     Zhengzheng Zhu (Oversea Business Development, PeakSonic)

    The research covers brief profiles of key players engaged in the development of handheld ultrasonic diagnostic imaging devices; other popular industry players featured in the report include:
     Aidmax Medical
     Beijing Konted Medical Technology
     Biim Ultrasound
     BreastIT
     CJ Medical
     Guangzhou Top Medical Equipment
     Healcerion
     Interson Medical Instruments
     Somax Systems
     VINNO
     WuHan Youkey Bio-Medical Electronics
     Yor Labs

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/handheld-imaging-devices/319.html

    You may also be interested in the following titles:
    1. Large Volume Wearable Injectors Market (5th Edition), 2020-2030
    2. Companion Diagnostics Market (2nd Edition), 2019-2030
    3. Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Gaurav Chaudhary
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Request Sample - Handheld Ultrasound Imaging Devices | Industry Analysis | Market Size | 2030
    With enhanced demand for point-of-care imaging solution, the handheld ultrasound imaging devices market is estimated to reach USD 1.2 billion by 2030
    WWW.ROOTSANALYSIS.COM
    0 0 Commenti 0 Shares
  • Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract manufacturing market.

    Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers

    Roots Analysis is pleased to announce the publication of its recent study, titled, “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030.”

    The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of HPAPIs and cytotoxic drugs. The study also features a detailed analysis of the key drivers and trends related to this evolving domain. In addition to other elements, the study includes:
     A detailed assessment of the current market landscape of companies offering contract services for manufacturing HPAPIs and cytotoxic drugs.
     A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, featuring insightful representations.
     Detailed profiles of leading contract manufacturers of HPAPI and cytotoxic drugs (shortlisted on the basis of proprietary criterion).
     An analysis of the partnerships that have been established in this domain, in the recent past.
     An analysis of the various expansion initiatives undertaken by the players in this domain.
     An estimate of the overall, installed capacity for manufacturing HPAPIs and cytotoxic drugs based on data reported by industry stakeholders in the public domain.
     A qualitative analysis to decide whether to manufacture the potent products in-house or engage the services of a CMO.
     A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution.
     A case study on the antibody drug conjugates (ADCs) manufacturing market, highlighting a list of contract service providers and in-house manufacturers in this domain.
     A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
     Type of Product
     HPAPIs
     Highly Potent Finished Dosage Forms

     Company Size
     Small-sized
     Mid-sized
     Large / Very Large

     Scale of Operation
     Preclinical / Clinical
     Commercial

     Type of Pharmacological Molecule
     Small Molecules
     Biologics

     Type of Highly Potent Finished Dosage Form
     Injectables
     Oral Solids
     Creams
     Others
     Key geographical regions
     North America
     Europe
     Asia Pacific
     Rest of the World

    The report includes detailed transcripts of discussions held with the following senior level representatives of stakeholder companies:
     Antonella Mancuso (Vice President and Chief Operating Officer, BSP Pharmaceuticals) and Maria Elena Guadagno (Business Director, BSP Pharmaceuticals)
     Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)
     Kevin Rosenthal (Business Head, Formulations and Finished Products, Alphora Research)
     Jennifer L Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
     Roberto Margarita (Business Development Director, CordenPharma)
     Allison Vavala (Senior Manager, Business Development, Helsinn)
     Mark Wright (Site Head, Piramal Healthcare)
     Javier E. Aznárez Araiz (Business Development Technician, Idifarma)

    Key companies covered in the report
     AbbVie Contract Manufacturing
     CARBOGEN AMCIS
     Catalent
     Evonik
     Formosa Laboratories
     Intas
     Lonza
     MabPlex
     Pfizer CentreOne

    For more information please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

    Other Recent Offerings
    1. Antibody Contract Manufacturing Market, 2020 – 2030
    2. Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030
    3. Biopharma Contract Manufacturing Market (3rd Edition), 2019 – 2030



    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Gaurav Chaudhary
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) | Industry Analysis | Market Size | 2030
    Market research report on the future of HPAPI and Cytotoxic drugs manufacturing, focus on current market landscape and future growth opportunities
    WWW.ROOTSANALYSIS.COM
    0 0 Commenti 0 Shares

Nessun risultato da mostrare

Nessun risultato da mostrare

Nessun risultato da mostrare